Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for diagnostic and therapeutic procedures in critical care and surgery. It operates in the United States, Europe, the Middle East, Africa, Asia Pacific, and other international markets. The company offers vascular and emergency medicine products, interventional products, and surgical products under brands such as Arrow, QuikClot, Weck, and Deknatel. It serves hospitals, healthcare providers, and medical device manufacturers, and also sells products online. Incorporated in 1943, Teleflex is headquartered in Wayne, Pennsylvania.
Teleflex's portfolio reshape brings FDA wins but integration and guidance cuts weigh
▲
FDA approves first freeze-dried plasma product The FDA approved EZPLAZ, the first licensed freeze-dried plasma, a new product for bleeding emergencies. It opens a new market and supports long-term growth, though near-term sales will be small. This is a genuine new regulatory win that lifts the growth story.
New FDA approval is a concrete positive catalyst for future revenue.
▲
Freesolve heart scaffold trial advances Teleflex started a large global trial for its Freesolve resorbable magnesium scaffold and finished another trial early. Positive early data support a future product that could compete in heart stents. This is a long-term pipeline boost, not immediate revenue.
New trial milestone shows pipeline progress that could drive future growth.
▼
2026 revenue growth outlook cut on slow integration Teleflex lowered its 2026 revenue growth forecast to 3.5%-4.5% from 4.5%-5.5%, blaming slower integration of its vascular intervention business. The interventional segment revenue fell 1% in Q2. This directly reduces expected sales and pressures the stock.
Guidance cut is a key negative driver for the stock price.
▼
2026 GAAP earnings guidance cut after weak Q2 Teleflex cut its 2026 GAAP EPS guidance to $2.54-$2.84 after lower Q2 net income and extended integration timelines. While adjusted EPS was raised, the GAAP cut highlights profitability challenges. Investors focus on how the portfolio reshape converts to sustainable earnings.
Earnings guidance cut is a direct negative for investor sentiment and valuation.
Q3 2026
▲2▼2
Teleflex's portfolio reshape brings FDA wins but integration and guidance cuts weigh
▲
FDA approves first freeze-dried plasma product The FDA approved EZPLAZ, the first licensed freeze-dried plasma, a new product for bleeding emergencies. It opens a new market and supports long-term growth, though near-term sales will be small. This is a genuine new regulatory win that lifts the growth story.
New FDA approval is a concrete positive catalyst for future revenue.
▲
Freesolve heart scaffold trial advances Teleflex started a large global trial for its Freesolve resorbable magnesium scaffold and finished another trial early. Positive early data support a future product that could compete in heart stents. This is a long-term pipeline boost, not immediate revenue.
New trial milestone shows pipeline progress that could drive future growth.
▼
2026 revenue growth outlook cut on slow integration Teleflex lowered its 2026 revenue growth forecast to 3.5%-4.5% from 4.5%-5.5%, blaming slower integration of its vascular intervention business. The interventional segment revenue fell 1% in Q2. This directly reduces expected sales and pressures the stock.
Guidance cut is a key negative driver for the stock price.
▼
2026 GAAP earnings guidance cut after weak Q2 Teleflex cut its 2026 GAAP EPS guidance to $2.54-$2.84 after lower Q2 net income and extended integration timelines. While adjusted EPS was raised, the GAAP cut highlights profitability challenges. Investors focus on how the portfolio reshape converts to sustainable earnings.
Earnings guidance cut is a direct negative for investor sentiment and valuation.
News & notes movingTFX
United States
TFX▲
Nvidia Authorizes Additional $150 Billion Buyback, Total Reaches $235 Billion
Nvidia authorized an additional $150 billion for its share buyback program, bringing the total authorization to $235 billion, and the graphics chip designer's shares rose 2.7% on Monday. Pacific Biosciences of California climbed 5.8% after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. Palo Alto Networks gained 5.1% after BTIG raised its price target on the cybersecurity platform provider to $425 from $404 and reiterated a Buy rating following discussions with management. Teleflex rose 4.5% after BofA Securities upgraded the medical technology company's stock from Neutral to Buy and raised its price target.
NVDA · Capital · Positive Nvidia authorized an additional $150 billion share buyback, bringing total authorization to $235 billion.
PANW · Capital · Positive BTIG raised its price target on Palo Alto Networks to $425 from $404 and reiterated a Buy rating.
TFX · Capital · Positive BofA Securities upgraded Teleflex from Neutral to Buy and raised its price target.
PACB · Demand · Positive Sampled announced a five-year contract worth up to $27.1 million from the VA to support research using PacBio Revio sequencing systems.
Teleflex Appoints Sean M. Salmon to Board of Directors
Teleflex Incorporated has appointed Sean M. Salmon, a veteran medical technology executive, to its Board of Directors, effective September 8, 2026. Salmon brings over three decades of leadership experience, including more than 20 years at Medtronic, where he most recently served as Executive Vice President and President of its Cardiovascular Portfolio, a business with fiscal 2025 revenue of approximately $12.5 billion. He currently serves as an independent director of Adagio Medical Holdings. Following his appointment, one third of the Board has been refreshed in 2026, and the Board now comprises nine directors, eight of whom are independent. Salmon will also serve on the Growth and Operating Committee, which supports the company's strategic transformation.
Teleflex Cuts 2026 Earnings Guidance After Weaker Second Quarter
Teleflex Incorporated reported second-quarter sales of US$570.33 million but lower net income of US$99.69 million year-on-year, and cut its 2026 GAAP EPS guidance to US$2.54 to US$2.84 while affirming revenue guidance of US$2.26 billion to US$2.28 billion. The company also completed a US$250 million repurchase of 1,900,000 shares and affirmed a quarterly US$0.34 dividend payable on September 30, 2026. The lowered earnings outlook and extended integration timelines for the Vascular Intervention acquisition are sharpening investor focus on how Teleflex converts its portfolio reshaping into sustainable profitability and cash returns.
TFX · Capital · Negative Teleflex cut its 2026 GAAP EPS guidance to $2.54-$2.84, reflecting weaker Q2 net income and extended integration timelines for the Vascular Intervention acquisition.
Teleflex Cuts 2026 Revenue Growth Outlook as Vascular Intervention Integration Slows
Teleflex reduced its 2026 pro forma adjusted constant currency revenue growth guidance to 3.5%–4.5% from 4.5%–5.5%, citing a slower-than-expected integration of the vascular intervention business. The interventional segment saw revenue decline 1% in the second quarter, falling short of expectations due to ongoing order-to-cash transitions, distributor changes, and sales force realignment. Despite the headwinds, the company delivered better-than-expected revenue, adjusted margins, and adjusted EPS in Q2, with strength in vascular and surgical units. Teleflex also closed its OEM divestiture, generating approximately $1.5 billion in proceeds to fund debt reduction and share repurchases, including a $250 million buyback completed in the quarter and an additional $250 million accelerated share repurchase set to begin on August 7, 2026. The company raised its full-year adjusted EPS guidance to $6.90–$7.20, reflecting the benefit of share repurchases and lower net interest expense. New CEO Jason Weidman, who brings 20 years of interventional experience, expressed strong conviction in the long-term prospects of the interventional business and expects to provide more details on his strategic vision by the next earnings call.
Teleflex secures FDA approval for freeze-dried plasma and completes $1.5 billion OEM sale
Teleflex has secured FDA approval for its EZPLAZ Freeze Dried Plasma and completed a $1.5 billion OEM divestiture, refocusing its portfolio. The stock has gained 13.71% over the past 90 days and delivered a 23.40% one-year total shareholder return. A widely followed analyst narrative estimates fair value at $148.55, slightly above the last close of $140.12, implying the stock is modestly undervalued. That narrative assumes annual revenue growth of 6.1% over the next three years and a profit margin recovery from 0.1% to 11.7%, though execution risks remain if UroLift weakness persists or Biotronik integration pressures margins.
FDA Approves Teleflex's EZPLAZ, the First Licensed Freeze-Dried Plasma Product
Teleflex Incorporated announced that the U.S. FDA has approved its Biologics License Application for EZPLAZ Freeze Dried Plasma, making it the first FDA-licensed freeze-dried plasma product and Teleflex's first biologics license for a blood component. EZPLAZ is indicated for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled hemorrhage, when plasma is needed and other plasma products are not available. Unlike current Emergency Use Authorization products packaged in glass bottles, EZPLAZ uses a patented flexible plastic bag technology designed for easier transport and storage in critical settings such as ambulances, hospitals, and battlefields. The Defense Health Agency partnered with Teleflex through its Warfighter Protection and Acute Care program to develop shelf-stable blood products for frontline medical teams. Teleflex shares closed Wednesday at $134.65, up 0.34%, and rose 1.75% in pre-market trading to $137.00.
BMO names Intuitive Surgical, Globus Medical, Teleflex as top MedTech picks
BMO Capital Markets has named Intuitive Surgical, Globus Medical, and Teleflex as its highest-conviction picks in the medical technology sector, initiating coverage with Outperform ratings and calling the beaten-down group a buying opportunity. Analyst Vik Chopra noted that MedTech stocks trade roughly 31% below their 10-year relative average, approaching the widest discount to the S&P 500 in a decade, while demand for hospital procedures remains strong. He attributed the weakness to fund flows and policy noise rather than fundamentals, describing the sector as under-owned and under-appreciated with the marginal buyer absent. Intuitive Surgical, his top pick, trades at about a 31% discount to its three-year historical multiple despite having the strongest fundamental profile among peers. Globus Medical was highlighted for sector-leading margin growth partly driven by its Nevro acquisition, and Teleflex was cited for a 2027 earnings inflection not yet reflected in consensus. Price targets were set at $518 for Intuitive Surgical, $94 for Globus Medical, and $159 for Teleflex.
GMED · Capital · Positive BMO initiated coverage with Outperform rating and $94 price target, citing sector-leading margin growth and Nevro acquisition.
ISRG · Capital · Positive BMO named Intuitive Surgical as top pick with Outperform rating and $518 price target, noting it trades at a 31% discount to historical multiple despite strong fundamentals.
TFX · Capital · Positive BMO initiated coverage with Outperform rating and $159 price target, citing a 2027 earnings inflection not yet reflected in consensus.
Surgical equipment and consumables specialty stocks reported a strong first quarter, with the four companies tracked by StockStory beating revenue consensus by 2.7% on average. Integra LifeSciences posted revenue of $391.9 million, up 2.4% year-on-year and 2.6% above estimates, while raising its full-year EPS guidance; its shares have surged 64.9% since the report. Intuitive Surgical delivered the biggest beat, with revenue of $2.77 billion exceeding expectations by 5.8%, though its stock fell 10.6%. Teleflex grew revenue 32.3% to $548.3 million but missed full-year EPS guidance, and LeMaitre Vascular reported $66.55 million in revenue, in line with estimates, while beating next-quarter EPS guidance.
Teleflex Begins Enrollment in Global BIOMAG-III Pivotal Trial for Freesolve Resorbable Magnesium Scaffold
Teleflex has initiated enrollment in the BIOMAG-III Study, a landmark global pivotal trial evaluating its Freesolve Resorbable Magnesium Scaffold. The randomized controlled trial will enroll 1,859 patients at up to 120 sites worldwide, including up to 60 in the United States, and compare Freesolve RMS to Xience Drug-Eluting Stent on Target Lesion Failure at 12 months. The first U.S. patient was implanted by Dr. Itsik Ben-Dor at MedStar Health in Washington, D.C. Teleflex also announced that enrollment in the BIOMAG-II Study, a separate 1,861-patient randomized trial comparing Freesolve RMS to Xience DES across 20 countries in Europe and Asia Pacific, was completed ahead of schedule. Additionally, positive four-year data from the BIOMAG-I first-in-human study showed a 3.5% Target Lesion Failure rate with no new clinical events between two and four years.
USA